Emerging evidence supports the concept that T helper type 17 (T H 17) cells, in addition to mediating autoimmunity, have key roles in mucosal immunity against extracellular pathogens. Interleukin-22 (IL-22) and IL-17A are both effector cytokines produced by the T H 17 lineage, and both were crucial for maintaining local control of the Gram-negative pulmonary pathogen, Klebsiella pneumoniae. Although both cytokines regulated CXC chemokines and granulocyte colony-stimulating factor production in the lung, only IL-22 increased lung epithelial cell proliferation and increased transepithelial resistance to injury. These data support the concept that the T H 17 cell lineage and its effector molecules have evolved to effect host defense against extracellular pathogens at mucosal sites.
IL-17 is a proinflammatory cytokine implicated in many autoimmune diseases [1] [2] [3] . Recently, it has been shown that IL-17-producing T cells belong to a unique subset of T cells, T H 17 cells, that develop under the control of transforming growth factor-b and IL-6 in mice and IL-23 and IL-1b in humans via the transcription factor RORgt (refs. [4] [5] [6] [7] [8] [9] [10] . IL-17A and IL-17F are important molecules in neutrophil recruitment and granulopoiesis 2 . IL-23 has also been shown to be crucial as an upstream regulator of IL-17 production in vivo 11, 12 . Mice with a homozygous deletion of the gene encoding IL-17 receptor A (Il17ra), which can bind both IL-17A and IL-17F (ref. 13) , are susceptible to lung infection with the Gram-negative bacteria K. pneumoniae. These mice do not mount a normal mucosal granulocyte colony-stimulating factor (G-CSF) response, which leads to defective granulopoiesis in response to the infection 14 . Antibodies to IL-17A have also been shown to impair intra-abdominal abscess formation in response to Bacteroides fragilis 15 and host defense against Bordetella pertussis 16 and Mycoplasma pulmonis 17 .
IL-22 is an IL-10 family cytokine member 18 that was originally thought to be predominantly expressed in T H 1 cells and has been shown to induce the antimicrobial peptides human b-defensin 2 and b-defensin 3; with IL-17A, IL-22 augments expression of the calciumbinding proteins S100A7, S100A8 and S100A9 in skin keratinocytes 19, 20 . It has recently been shown that T H 17 cells grown in vitro also produce IL-22, and in vitro production was optimized when IL-23 was present 20 .
On the basis of this evidence, we hypothesized that IL-22 may be a crucial effector molecule in host defense against Gram-negative bacterial infection in the lung. Here we show that human bronchial epithelial (HBE) cells express IL-22R and that IL-22 and IL-17 induce host defense genes, as well as increase the clonogenic potential of HBE cells. Using an experimental model of Gram-negative pneumonia, we show that IL-22 is produced in a time-dependent fashion, similarly to IL-17A and IL-17F (ref. 12) , and is regulated by IL-23. Neutralization of IL-22 resulted in a marked bacterial dissemination from the lung that was exacerbated by the absence of IL-17A. IL-22 also increased the expression of host defense genes in mouse lung epithelium and, among these, lipocalin-2 was required for IL-22-augmented epithelial antimicrobial activity in vitro. These data demonstrate that IL-22 has a crucial role in mucosal host defense, and they support the concept that the T H 17 cell lineage and the effector molecules produced by these cells evolved to effect host defense against extracellular pathogens at mucosal sites.
RESULTS
The production of IL-17A and IL-17F in infected tissue is regulated by IL-23 (ref. 12); however, IL-23 has been shown to be only marginally involved in primary infections with pathogens that require T H 1 immunity, such as Mycobacterium tuberculosis 21 . Similar to mice deficient in IL-23 (Il23a -/-), mice deficient in IL-17RA, which is required for IL-17A and IL-17F signaling 13 , are not more susceptible to H37Rv M. tuberculosis infection than wild-type mice (Supplementary Fig. 1 online) . Moreover, IL-17RA signaling is not required for host defense against another T H 1-dependent pathogen, Listeria monocytogenes ( Supplementary Fig. 2 online), and these mice have normal interferon-g responses upon antigen recall to the pathogen (Supplementary Fig. 2 ). This is consistent with normal T H 1 immunity and host resistance against L. monocytogenes in Il22 À/À mice 22 . These data suggest that T H 17 cells may be important for host defense against extracellular pathogens because they produce IL-17A and IL-22.
Expression of IL-22R and activity of IL-22 on HBE cells IL-22R is expressed on polarized, ciliated, primary HBE cells (Fig. 1a) , and its expression at the mRNA level is not altered after 24-h stimulation with IL-17A, IL-22 or both cytokines ( Supplementary  Fig. 3a online) . To examine gene expression, we stimulated HBE cells with 10 ng/ml IL-17A, 20 ng/ml IL-22 or a combination of both for 24 h and harvested total RNA for microarray analysis. The combination of IL-22 with IL-17A markedly induced several host defense genes, including those encoding human b-defensin 2 (DEFB4), psoriasin (S100A7) and calgranulin C (S100A12), as well as IL19, CSF3, IL1F9, DUOX2, CXCL1, CXCL5, CXCL9 and CCL3 (Fig. 1b) . We confirmed CSF3 induction both at the mRNA level by real-time PCR (Supplementary Fig. 3b) and at the protein level (Fig. 1c) . Moreover, we observed a significant increase in IL-17A-induced IL-6 production in HBE cells by IL-22 (Fig. 1d) .
As IL-22 has been implicated in wound repair in the skin 5 , we examined whether IL-22 increases the clonogenic frequency of HBE cells and whether IL-22 affects epithelial barrier function. Treatment with IL-22 at a concentration of 200 ng/ml (but not 20 ng/ml, data not shown) significantly increased the clonogenic potential of HBE cells compared to treatment with media alone, or compared to treatment with 100 ng/ml of IL-17A (Fig. 1e) . We next evaluated whether IL-22 affected the maintenance of transepithelial resistance in injured epithelium. We created a 10-mM wound in well-differentiated, polarized HBE cells and found that the addition of IL-22 at a dose as low as 20 ng/ml significantly enhanced recovery of epithelial resistance (Fig. 1f) . The recovery of resistance occurred as early as 6 h after the injury, whereas control cells recovered over a 36-h time period. IL-17A at doses of 10 or 100 ng/ml had no activity in this assay (data not shown).
Requirement of IL-22 in host defense against K. pneumoniae To examine whether IL-22 is important for mucosal host defense in the lung, we used a well-established model of K. pneumoniae pulmonary infection. Similar to the previously observed time course for IL-17A and IL-17F production (ref. 12), IL-22 was detectable at the message level as early as 6 h (Fig. 2a) and at the protein level in lung homogenate as early as 16 h in mice infected with K. pneumoniae (Fig. 2b) , and its expression was significantly elevated (P o 0.05) compared to that in uninfected mice. Additionally, it has been reported that T H 17 cells express CCR4 and CCR6 (ref. 23) , and thus we assessed the expression of the genes encoding the ligands for these receptors, Ccl17, Ccl20 and Ccl22. Both Ccl17 and Ccl20 expression was significantly increased (P o 0.05) at 4 h in lung tissue of mice infected with K. pneumoniae ( Supplementary Fig. 4 online), and Ccl20 expression continued to increase at 16 h. Ccl22 expression, however, showed a steady decline in this model ( Supplementary Fig. 4) .
We then investigated the potential cellular sources of IL-22 in our model system. Rag2 À/À Il2rg À/À mice (deficient in natural killer, T and B cells) were infected with K. pneumoniae, and their lungs were harvested at 24 h after infection ( Supplementary Fig. 5a online). As expected, Rag2 À/À Il2rg À/À mice produced no detectable IL-22 compared to their infected, wild-type (WT) counterparts. To further confirm that T cells produce IL-22 in response to K. pneumoniae, we isolated CD90 + T cells from lungs harvested from infected mice and uninfected controls and then assessed IL-22 precursor frequency by enzyme-linked immunosorbent spot (ELISPOT). There was a significant increase in IL-22-producing CD90 + cells in K. pneumoniae-infected mice compared to uninfected controls ( Supplementary  Fig. 5b ). There were no spots from CD90 -cells (data not shown).
We next determined the survival of WT and Il17a À/À mice treated with control antibody or antibody to IL-22 and challenged with 1 Â 10 4 colony-forming units (CFU) of K. pneumoniae (Fig. 2c) . Compared to WT mice or Il17a À/À mice given control antibody, WT mice treated with antibody to IL-22 were moribund 24 h after infection and had to be killed. Mice treated with antibody to IL-22 had significantly (P o 0.05) greater numbers of CFU in the lung compared to control mice ( Fig. 2d) and also showed increased dissemination to the spleen (Fig. 2e) . Administration of antibodies to IL-22 did not affect induction of IL-17A in this model (Supplementary Fig. 6 online). Consistent with a more crucial role for IL-22 than for IL-17A in mucosal host defense, increased dissemination to the spleen was not detectable in Il17a À/À mice until 48 h after infection (Fig. 2f) . Moreover, administration of IL-22-specific antibody to Il17a À/À mice before infection with K. pneumoniae resulted in significantly greater bacterial growth in the lung (Fig. 2g) and significantly more bacterial dissemination to the spleen (Fig. 2h ) at 24 h after infection. To exclude the possibility of IL-17F compensation in Il17a À/À mice, we also assessed IL-17F levels in WT and Il17a À/À mice, and, at 18 h after infection, IL-17F was similarly induced in both strains of mice (data not shown).
Similarly to Il17ra À/À (ref. 14) and Il23a À/À (ref. 12) mice, Il17a À/À mice had significantly lower amounts of G-CSF and CXCL1 in the bronchoalveolar lavage (BAL) fluid at 24 h compared to WT mice (Fig. 3a,b) . However, compared to WT mice, mice treated with antibody to IL-22 showed no difference in BAL G-CSF and CXCL1 protein concentrations (Fig. 3a,b) . Despite the lack of a function for IL-22 in regulation of G-CSF and CXCL1 in WT mice, Il17a À/À mice given antibody to IL-22 had lower Csf3 abundance compared to Il17a À/À mice given control antibody, but this difference was not statistically significant. Moreover, CXCL1 expression was partially dependent on both IL-17A and IL-22, as it was lower in Il17a À/À mice treated with antibody to IL-22 (Fig. 3b) . In contrast to G-CSF, IL-22 was crucial for IL-6 production in the lung, as both antibody to IL-22-treated WT and Il17a À/À mice had statistically significant reductions in BAL IL-6 abundance 24 h after infection (Fig. 3c) . A similar pattern was also observed with CCL3 (Fig. 3d) , where mice treated with antibody to IL-22 had significantly lower CCL3 in the BAL fluid at 24 h after infection compared to control mice. In the absence of IL-17A, antibody neutralization of IL-22 resulted in a further reduction in IL-6 and CCL3 abundance, suggesting a requirement for both IL-17A and IL-22 in this response. 1,000 CXCL1 (pg/ml) IL-6 (pg/ml) CCL3 (pg/ml) 500
Control Control markedly attenuated in Il23a À/À mice (Fig. 4a) . We next examined whether administration of recombinant IL-22, IL-17A or both intratracheally 12 h after infection with 1 Â 10 3 CFU of K. pneumoniae could augment mucosal host defense. Even at this lower bacterial inoculum, as previously reported, Il23a À/À mice treated with vehicle had higher organism burdens in the lung compared to WT mice (Fig. 4b) . Treatment with recombinant IL-22, IL-17A or both significantly reduced recoverable CFU in the lung at 24 h (Fig. 4b) . Furthermore, there was significantly less bacterial dissemination to the spleen in mice given recombinant IL-22, IL-17A or both cytokines (Fig. 4c) .
As IL-22R is expressed in epithelial cells, we tested whether this is the site of action of recombinant IL-22 in the lung using in situ hybridization for Cxcl1 and the closely related Cxcl2 and Cxcl9 (Fig. 5) , as these genes have been shown to be regulated by IL-17A in vivo in pulmonary infection 14, 24 . WT mice showed Cxcl9 transcripts in both airway cells and alveolar epithelial cells (Fig. 5) . Il23a À/À mice showed less staining in lung tissue (Fig. 5) ; however, administration of IL-22, IL-17A or the combination of IL-22 with IL-17A augmented hybridization signals for Cxcl1, Cxcl2 and Cxcl9 expression (Fig. 5) . Moreover, IL-22 treatment resulted in increased transcripts for Cxcl1, Cxcl2 and Cxcl9 in bronchiole epithelium (Fig. 5, black arrows) , whereas administration of IL-17A or the combination of IL-22 and IL-17A increased expression in bronchiole epithelium as well as in distal lung epithelium (Fig. 5, gray arrows) .
IL-22 regulates antimicrobial activity of lung epithelium
To investigate the gene expression and antimicrobial activity of IL-22 in mouse lung epithelium, we studied polarized primary mouse tracheal epithelial cells (MTECs). Cells were stimulated with 20 ng/ml IL-22 and 10 ng/ml IL-17, and Csf3 protein abundance was significantly (P o 0.05) increased by the combination of IL-22 and IL-17 (Fig. 6a) . This was also the case with Cxcl1 (Fig. 6b) . To analyze gene expression in these cells, we performed microarray analysis. There was upregulation of several host defense genes, including Lcn2 (encoding lipocalin-2), Cxcl1, Cxcl5, Pigr (encoding the polymeric immunoglobulin receptor) and Cxcl9 (Fig. 6c) . Lipocalin-2 is a protein known to have a function in innate immune response through its ability to sequester iron from bacterial organisms such as Escherichia coli 25, 26 .
To investigate whether IL-22 has an antimicrobial function in vitro, we applied K. pneumoniae apically to MTECs that had been pretreated with IL-22, IL-17A or both cytokines. IL-22 significantly (P o 0.05) augmented killing of K. pneumoniae (Fig. 6d) . This was dependent on the expression of lipocalin-2 as IL-22-induced killing was significantly abrogated in MTEC cultures derived from Lcn2 À/À mice compared to WT controls (Fig. 6d) .
T cells from explanted cystic fibrosis lymph nodes produce IL-22
Gram-negative bacterial pneumonia is common in immunocompromised individuals such as organ transplant recipients 27 . In order to study IL-22 in this cohort, we obtained samples of BAL fluid from seven subjects who were lung transplant recipients with bacterial pneumonia. Although most subjects had elevated CXCL8 levels (a measure of sample integrity), none had any significant detectable levels of IL-22 or IL-17A (Supplementary Table 1 online) . This was not surprising to us in light of the fact that all individuals were maintained on T cell immunosuppression to prevent rejection of their transplanted lungs. These data are in contrast to the elevated sputum IL-17A and IL-17F levels observed during Pseudomonas aeruginosa lung infection in subjects with cystic fibrosis who have normal T cell function 28 . On the basis of these observations, we investigated IL-22 expression during this gram-negative bacterial lung infection. 
Cxcl1
Cxcl2 Cxcl9 Figure 5 Il23a À/À mice rescued with IL-22, IL-17A and both cytokines have augmented Cxcl1, Cxcl2 and Cxcl9 expression in airways and alveolar epithelium. WT and Il23a À/À mice were infected with K. pneumoniae, and 12 h after infection, Il23a À/À mice were rescued with 1 mg of vehicle (PBS), IL-22, IL-17A or both cytokines. A representative in situ hybridization for Cxcl1, Cxcl2 and Cxcl9 is depicted. Il23a À/À mice had reduced staining for Cxcl1, Cxcl2 and Cxcl9 in lung tissue compared with WT mice. After administration of IL-22, IL-17A or combination of IL-22 and IL-17A, Il23a À/À mice had significantly increased expression of all three chemokines both in distal airway (black arrows) and alveolar epithelium (gray arrows).
We studied banked BAL fluid samples from individuals with cystic fibrosis undergoing a clinical exacerbation with P. aeruginosa infection and from control individuals without cystic fibrosis. Compared to the controls, IL-23, IL-17A and IL-17F were significantly elevated in BAL fluid of subjects with cystic fibrosis (Fig. 6e) . Of note, very little IL-22 was detected in these samples (Fig. 6e) . Based on the fact that in our mouse pneumonia model, IL-22 levels were higher in lung tissue than in BAL, we sought to determine whether IL-22 responses were elevated in lung lymphoid tissue in humans. We isolated cells from explanted hilar lymph nodes from individuals with end-stage cystic fibrosis undergoing lung transplantation (n ¼ 5), in addition to uninfected control lung lymph nodes from individuals without cystic fibrosis (n ¼ 2). Compared to uninfected lung lymph nodes from individuals without cystic fibrosis, dissociated lymph nodes cells from P. aeruginosa-infected subjects with cystic fibrosis had significantly increased spontaneous production of IL-17A (Fig. 6f) , IL-17F and IL-22 (Fig. 6g) , and production of these cytokines were stimulated with concanavalin A (ConA), a glycoprotein that stimulates T lymphocyte proliferation (Fig. 6f,g) .
DISCUSSION
These data demonstrate that IL-22 has a more crucial role than IL-17A in mucosal host defense and in our model of experimental bacterial pneumonia. IL-22 expression in vivo is regulated by IL-23, and rescue of Il23a À/À mice is associated with increased lung epithelial expression of CXCL1, CXCL2 and CXCL9. Similar to the situation in Il17ra À/À mice, IL-17A was crucial for the induction of G-CSF, a key regulator of granulopoiesis in response to an infectious challenge 14 , in the lung. However, IL-22 was more important than IL-17A in regulating pulmonary IL-6 and CCL3 production. Studies in Il17a À/À mice show that IL-6 and CCL3 are coordinately regulated by both T H 17 effectors, suggesting that the synergy observed with IL-17A and IL-22 in human bronchial epithelial cells in terms of gene expression is relevant in the in vivo setting as well. Additional activities of IL-22 not shared by IL-17A were the effect of increasing clonogenic frequencies of HBE cells, as well enhancing repair of transepithelial resistance. These activities of IL-22 may be crucial for maintaining barrier function at epithelial surfaces. In support of this, WT and Il17a À/À mice that received antibody to IL-22 had more rapid bacterial dissemination outside of the lung compared with mice given control antibody. In vitro MTEC studies show that a key gene regulated by IL-22 in the epithelium is lipocalin-2, which is required for epithelial host defense against K. pneumoniae in vitro. This is consistent with the fact that Lcn2 À/À mice are susceptible to certain Gram-negative bacteria, depending upon which siderophores they express 25, 26 .
Furthermore, we show that IL-17R signaling is dispensable for host defense to a primary challenge with M. tuberculosis or L. monocytogenes, two intracellular pathogens that require T H 1 immunity. These data strongly suggest that the T H 17 lineage evolved to mediate host defense at mucosal and serosal surfaces against extracellular pathogens. Additionally, neutralization of IL-17A has been shown to abrogate host defense against lung pathogens, such as K. pneumoniae and M. pulmonis 14, 17 , systemic infection with the fungus Candida albicans 29 , as well as in the setting of intra-abdominal infection, B. fragilis 15 and E. coli 30 . Potential host defense mechanisms downstream from IL-22 and IL-17A, in addition to granulopoiesis, are the regulation of chemokine gradients and the mucosal production of antimicrobial proteins such as b-defensins 31 and calgranulins 20 . It is noteworthy that IL-22 responses are significantly elevated in lung lymphoid tissue from human subjects with cystic fibrosis. This is consistent with elevated levels of antimicrobial peptides in the sputum Fig. 2 ). C.A.M. performed the experiments with M. tuberculosis ( Supplementary Fig. 1 Figure 1 . Y.I. provided Il17A À/À mice, as well as useful discussion in experimental design. J.K.K. was responsible for experimental design, microarray analysis and final manuscript preparation.
